Merck's Keytruda Chemo-Combo Data Has Big Implications For Future Of Immuno-Oncology

Merck’s strong Phase II data testing Keytruda with chemotherapy in first-line lung cancer may put pressure on future IO/IO combinations when it comes to toxicity, efficacy and – importantly – cost.